{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:45:47Z","timestamp":1793151947257,"version":"4.5.0"},"reference-count":184,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T00:00:00Z","timestamp":1604707200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T00:00:00Z","timestamp":1604707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["(81970184, U1904139)"],"award-info":[{"award-number":["(81970184, U1904139)"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011447","name":"Science and Technology Department of Henan Province","doi-asserted-by":"publisher","award":["(182102310114)"],"award-info":[{"award-number":["(182102310114)"]}],"id":[{"id":"10.13039\/501100011447","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of clinically aggressive diseases associated with poor prognosis. Except for ALK\u2009+\u2009anaplastic large-cell lymphoma (ALCL), most peripheral T-cell lymphomas are highly malignant and have an aggressive disease course and poor clinical outcomes, with a poor remission rate and frequent relapse after first-line treatment. Aberrant epigenetic alterations play an important role in the pathogenesis and development of specific types of peripheral T-cell lymphoma, including the regulation of the expression of genes and signal transduction. The most common epigenetic alterations are DNA methylation and histone modification. Histone modification alters the level of gene expression by regulating the acetylation status of lysine residues on the promoter surrounding histones, often leading to the silencing of tumour suppressor genes or the overexpression of proto-oncogenes in lymphoma. DNA methylation refers to CpG islands, generally leading to tumour suppressor gene transcriptional silencing. Genetic studies have also shown that some recurrent mutations in genes involved in the epigenetic machinery, including TET2, IDH2-R172, DNMT3A, RHOA, CD28, IDH2, TET2, MLL2, KMT2A, KDM6A, CREBBP, and EP300, have been observed in cases of PTCL. The aberrant expression of miRNAs has also gradually become a diagnostic biomarker. These provide a reasonable molecular mechanism for epigenetic modifying drugs in the treatment of PTCL. As epigenetic drugs implicated in lymphoma have been continually reported in recent years, many new ideas for the diagnosis, treatment, and prognosis of PTCL originate from epigenetics in recent years. Novel epigenetic-targeted drugs have shown good tolerance and therapeutic effects in the treatment of peripheral T-cell lymphoma as monotherapy or combination therapy. NCCN Clinical Practice Guidelines also recommended epigenetic drugs for PTCL subtypes as second-line therapy. Epigenetic mechanisms provide new directions and therapeutic strategies for the research and treatment of peripheral T-cell lymphoma. Therefore, this paper mainly reviews the epigenetic changes in the pathogenesis of peripheral T-cell lymphoma and the advancement of epigenetic-targeted drugs in the treatment of peripheral T-cell lymphoma (PTCL).<\/jats:p>","DOI":"10.1186\/s13148-020-00962-x","type":"journal-article","created":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T08:02:38Z","timestamp":1604736158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma"],"prefix":"10.1186","volume":"12","author":[{"given":"Ping","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3581-551X","authenticated-orcid":false,"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,7]]},"reference":[{"issue":"20","key":"962_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"issue":"1","key":"962_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.5581\/1516-8484.20120013","volume":"34","author":"M Bellei","year":"2012","unstructured":"Bellei M, Chiattone CS, Luminari S, et al. T-cell lymphomas in South America and Europe. Rev Bras Hematol Hemoter. 2012;34(1):42\u20137.","journal-title":"Rev Bras Hematol Hemoter"},{"key":"962_CR3","unstructured":"NCCN Clinical Practice Guidelines in Oncology Version 1.2020 T-Cell Lymphomas."},{"issue":"9","key":"962_CR4","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1182\/blood-2016-08-692566","volume":"129","author":"A Broccoli","year":"2017","unstructured":"Broccoli A, Zinzani PL. Peripheral T-cell lymphoma, not otherwise specified. Blood. 2017;129(9):1103\u201312.","journal-title":"Blood"},{"key":"962_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.anndiagpath.2017.05.005","volume":"34","author":"C Cao","year":"2018","unstructured":"Cao C, Feng J, Gu H, et al. Distribution of lymphoid neoplasms in Northwest China: analysis of 3244 cases according to WHO classification in a single institution. Ann Diagn Pathol. 2018;34:60\u20135.","journal-title":"Ann Diagn Pathol"},{"issue":"7","key":"962_CR6","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ajh.24791","volume":"92","author":"JO Armitage","year":"2017","unstructured":"Armitage JO. The aggressive peripheral T-cell lymphomas: 2017. Am J Hematol. 2017;92(7):706\u201315.","journal-title":"Am J Hematol"},{"issue":"4","key":"962_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11912-017-0582-9","volume":"19","author":"RF Sandell","year":"2017","unstructured":"Sandell RF, Boddicker RL, Feldman AL. Genetic landscape and classification of peripheral T cell lymphomas. Curr Oncol Rep. 2017;19(4):28.","journal-title":"Curr Oncol Rep"},{"issue":"11","key":"962_CR8","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1182\/blood-2016-02-698977","volume":"128","author":"D Vallois","year":"2016","unstructured":"Vallois D, Dobay MP, Morin RD, et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood. 2016;128(11):1490\u2013502.","journal-title":"Blood"},{"issue":"7","key":"962_CR9","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","volume":"120","author":"F Lemonnier","year":"2012","unstructured":"Lemonnier F, Couronne L, Parrens M, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood. 2012;120(7):1466\u20139.","journal-title":"Blood"},{"issue":"2","key":"962_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/ng.2872","volume":"46","author":"M Sakata-Yanagimoto","year":"2014","unstructured":"Sakata-Yanagimoto M, Enami T, Yoshida K, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(2):171\u20135.","journal-title":"Nat Genet"},{"issue":"8","key":"962_CR11","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","volume":"119","author":"RA Cairns","year":"2012","unstructured":"Cairns RA, Iqbal J, Lemonnier F, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012;119(8):1901\u20133.","journal-title":"Blood"},{"issue":"4","key":"962_CR12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3324\/haematol.2017.182444","volume":"103","author":"MM Ji","year":"2018","unstructured":"Ji MM, Huang YH, Huang JY, et al. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified. Haematologica. 2018;103(4):679\u201387.","journal-title":"Haematologica"},{"issue":"1","key":"962_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","volume":"20","author":"C Quivoron","year":"2011","unstructured":"Quivoron C, Couronne L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011;20(1):25\u201338.","journal-title":"Cancer Cell"},{"issue":"1","key":"962_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1056\/NEJMc1111708","volume":"366","author":"L Couronne","year":"2012","unstructured":"Couronne L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med. 2012;366(1):95\u20136.","journal-title":"N Engl J Med"},{"issue":"2","key":"962_CR15","first-page":"275","volume":"1865","author":"A Kazanets","year":"2016","unstructured":"Kazanets A, Shorstova T, Hilmi K, Marques M, Witcher M. Epigenetic silencing of tumor suppressor genes: paradigms, puzzles, and potential. Biochim Biophys Acta. 2016;1865(2):275\u201388.","journal-title":"Biochim Biophys Acta"},{"key":"962_CR16","doi-asserted-by":"crossref","unstructured":"Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone Deacetylase Inhibitors as Anticancer Drugs. Int J Mol Sci. 2017. 18(7).","DOI":"10.3390\/ijms18071414"},{"issue":"6","key":"962_CR17","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1365-2559.2009.03290.x","volume":"54","author":"L Marquard","year":"2009","unstructured":"Marquard L, Poulsen CB, Gjerdrum LM, et al. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology. 2009;54(6):688\u201398.","journal-title":"Histopathology"},{"issue":"3","key":"962_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1365-2559.2008.03109.x","volume":"53","author":"L Marquard","year":"2008","unstructured":"Marquard L, Gjerdrum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology. 2008;53(3):267\u201377.","journal-title":"Histopathology"},{"issue":"14","key":"962_CR19","doi-asserted-by":"publisher","first-page":"5184","DOI":"10.1128\/MCB.02091-06","volume":"27","author":"HG Kasler","year":"2007","unstructured":"Kasler HG, Verdin E. Histone deacetylase 7 functions as a key regulator of genes involved in both positive and negative selection of thymocytes. Mol Cell Biol. 2007;27(14):5184\u2013200.","journal-title":"Mol Cell Biol"},{"issue":"22","key":"962_CR20","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1128\/MCB.00706-15","volume":"35","author":"KR Stengel","year":"2015","unstructured":"Stengel KR, Zhao Y, Klus NJ, et al. Histone deacetylase 3 is required for efficient T cell development. Mol Cell Biol. 2015;35(22):3854\u201365.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"962_CR21","first-page":"1415","volume":"18","author":"H Zhang","year":"2019","unstructured":"Zhang H, Lv H, Jia X, et al. Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma. Oncol Lett. 2019;18(2):1415\u201323.","journal-title":"Oncol Lett"},{"issue":"3","key":"962_CR22","doi-asserted-by":"publisher","first-page":"196","DOI":"10.2174\/157488410791498770","volume":"5","author":"JH Beumer","year":"2010","unstructured":"Beumer JH, Tawbi H. Role of histone deacetylases and their inhibitors in cancer biology and treatment. Curr Clin Pharmacol. 2010;5(3):196\u2013208.","journal-title":"Curr Clin Pharmacol"},{"issue":"6","key":"962_CR23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.cytogfr.2012.08.002","volume":"23","author":"L Icardi","year":"2012","unstructured":"Icardi L, de Bosscher K, Tavernier J. The HAT\/HDAC interplay: multilevel control of STAT signaling. Cytokine Growth Factor Rev. 2012;23(6):283\u201391.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"9","key":"962_CR24","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.cellsig.2013.05.007","volume":"25","author":"S Zhuang","year":"2013","unstructured":"Zhuang S. Regulation of STAT signaling by acetylation. Cell Signal. 2013;25(9):1924\u201331.","journal-title":"Cell Signal"},{"issue":"20","key":"962_CR25","doi-asserted-by":"publisher","first-page":"7765","DOI":"10.1073\/pnas.1205132109","volume":"109","author":"H Lee","year":"2012","unstructured":"Lee H, Zhang P, Herrmann A, et al. Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc Natl Acad Sci USA. 2012;109(20):7765\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5707","key":"962_CR26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1126\/science.1105166","volume":"307","author":"ZL Yuan","year":"2005","unstructured":"Yuan ZL, Guan YJ, Chatterjee D, et al. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science. 2005;307(5707):269\u201373.","journal-title":"Science"},{"issue":"5","key":"962_CR27","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1053\/j.gastro.2005.07.055","volume":"129","author":"S Ray","year":"2005","unstructured":"Ray S, Boldogh I, Brasier AR. STAT3 NH2-terminal acetylation is activated by the hepatic acute-phase response and required for IL-6 induction of angiotensinogen. Gastroenterology. 2005;129(5):1616\u201332.","journal-title":"Gastroenterology"},{"issue":"12","key":"962_CR28","doi-asserted-by":"publisher","first-page":"11528","DOI":"10.1074\/jbc.M413930200","volume":"280","author":"R Wang","year":"2005","unstructured":"Wang R, Cherukuri P, Luo J. Activation of Stat3 sequence-specific DNA binding and transcription by p300\/CREB-binding protein-mediated acetylation. J Biol Chem. 2005;280(12):11528\u201334.","journal-title":"J Biol Chem"},{"issue":"1","key":"962_CR29","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3892\/or.2013.2414","volume":"30","author":"J Li","year":"2013","unstructured":"Li J, Cui G, Sun L, et al. STAT3 acetylation-induced promoter methylation is associated with downregulation of the ARHI tumor-suppressor gene in ovarian cancer. Oncol Rep. 2013;30(1):165\u201370.","journal-title":"Oncol Rep"},{"key":"962_CR30","doi-asserted-by":"publisher","first-page":"10204","DOI":"10.1038\/ncomms10204","volume":"6","author":"J Albrengues","year":"2015","unstructured":"Albrengues J, Bertero T, Grasset E, et al. Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts. Nat Commun. 2015;6:10204.","journal-title":"Nat Commun"},{"issue":"12","key":"962_CR31","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1158\/0008-5472.CAN-18-0359","volume":"79","author":"G Gambi","year":"2019","unstructured":"Gambi G, Di Simone E, Basso V, et al. The transcriptional regulator Sin3A contributes to the oncogenic potential of STAT3. Cancer Res. 2019;79(12):3076\u201387.","journal-title":"Cancer Res"},{"issue":"29","key":"962_CR32","doi-asserted-by":"publisher","first-page":"26729","DOI":"10.1074\/jbc.C500186200","volume":"280","author":"P Bali","year":"2005","unstructured":"Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 2005;280(29):26729\u201334.","journal-title":"J Biol Chem"},{"issue":"1","key":"962_CR33","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/bjh.13400","volume":"170","author":"SE Bates","year":"2015","unstructured":"Bates SE, Eisch R, Ling A, et al. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data. Br J Haematol. 2015;170(1):96\u2013109.","journal-title":"Br J Haematol"},{"key":"962_CR34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-014-0088-y","volume":"7","author":"Z Zheng","year":"2014","unstructured":"Zheng Z, Cheng S, Wu W, et al. c-FLIP is involved in tumor progression of peripheral T-cell lymphoma and targeted by histone deacetylase inhibitors. J Hematol Oncol. 2014;7:88.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"962_CR35","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1038\/bcj.2015.83","volume":"5","author":"BC Valdez","year":"2015","unstructured":"Valdez BC, Brammer JE, Li Y, et al. Romidepsin targets multiple survival signaling pathways in malignant T cells. Blood Cancer J. 2015;5(10):e357.","journal-title":"Blood Cancer J"},{"issue":"10","key":"962_CR36","first-page":"5287","volume":"34","author":"N Kunami","year":"2014","unstructured":"Kunami N, Katsuya H, Nogami R, Ishitsuka K, Tamura K. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia\/lymphoma. Anticancer Res. 2014;34(10):5287\u201394.","journal-title":"Anticancer Res"},{"issue":"44","key":"962_CR37","doi-asserted-by":"publisher","first-page":"5957","DOI":"10.1038\/onc.2010.332","volume":"29","author":"GM Marshall","year":"2010","unstructured":"Marshall GM, Gherardi S, Xu N, et al. Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene. 2010;29(44):5957\u201368.","journal-title":"Oncogene"},{"issue":"33","key":"962_CR38","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1038\/onc.2011.533","volume":"31","author":"R Palermo","year":"2012","unstructured":"Palermo R, Checquolo S, Giovenco A, et al. Acetylation controls Notch3 stability and function in T-cell leukemia. Oncogene. 2012;31(33):3807\u201317.","journal-title":"Oncogene"},{"issue":"10","key":"962_CR39","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1158\/1078-0432.CCR-15-2388","volume":"23","author":"A Nebbioso","year":"2017","unstructured":"Nebbioso A, Carafa V, Conte M, et al. c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer. Clin Cancer Res. 2017;23(10):2542\u201355.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"962_CR40","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00109-010-0701-7","volume":"89","author":"C Zhu","year":"2011","unstructured":"Zhu C, Chen Q, Xie Z, et al. The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc. J Mol Med (Berl). 2011;89(3):279\u201389.","journal-title":"J Mol Med (Berl)"},{"issue":"5","key":"962_CR41","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1593\/neo.121784","volume":"15","author":"R Piazza","year":"2013","unstructured":"Piazza R, Magistroni V, Mogavero A, et al. Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2\/SIN3a deacetylating complex. Neoplasia. 2013;15(5):511\u201322.","journal-title":"Neoplasia"},{"issue":"1","key":"962_CR42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1172\/JCI69738","volume":"124","author":"AC West","year":"2014","unstructured":"West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014;124(1):30\u20139.","journal-title":"J Clin Invest"},{"issue":"44","key":"962_CR43","doi-asserted-by":"publisher","first-page":"16090","DOI":"10.1073\/pnas.0505585102","volume":"102","author":"Y Zhao","year":"2005","unstructured":"Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, Yu Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA. 2005;102(44):16090\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"962_CR44","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2174\/156800908783769355","volume":"8","author":"S Fulda","year":"2008","unstructured":"Fulda S. Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr Cancer Drug Targets. 2008;8(2):132\u201340.","journal-title":"Curr Cancer Drug Targets"},{"issue":"6","key":"962_CR45","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s10637-015-0290-y","volume":"33","author":"D Markozashvili","year":"2015","unstructured":"Markozashvili D, Ribrag V, Vassetzky YS. Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies. Invest New Drugs. 2015;33(6):1280\u201391.","journal-title":"Invest New Drugs"},{"issue":"3","key":"962_CR46","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1042\/BJ20111685","volume":"443","author":"K Gong","year":"2012","unstructured":"Gong K, Xie J, Yi H, Li W. CS055 (Chidamide\/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells. Biochem J. 2012;443(3):735\u201346.","journal-title":"Biochem J"},{"issue":"1","key":"962_CR47","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1089\/ars.2014.5863","volume":"23","author":"AC Chueh","year":"2015","unstructured":"Chueh AC, Tse JW, T\u00f6gel L, Mariadason JM. Mechanisms of histone deacetylase inhibitor-regulated gene expression in cancer cells. Antioxid Redox Signal. 2015;23(1):66\u201384.","journal-title":"Antioxid Redox Signal"},{"issue":"10","key":"962_CR48","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1080\/10428194.2017.1295143","volume":"58","author":"A Shustov","year":"2017","unstructured":"Shustov A, Coiffier B, Horwitz S, et al. Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials. Leuk Lymphoma. 2017;58(10):2335\u201341.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"962_CR49","doi-asserted-by":"publisher","first-page":"424","DOI":"10.7150\/ijms.30154","volume":"16","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Wang S, Chen J, Yu Z. Histone Deacetylases (HDACs) Guided novel therapies for T-cell lymphomas. Int J Med Sci. 2019;16(3):424\u201342.","journal-title":"Int J Med Sci"},{"issue":"2","key":"962_CR50","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1365-2141.2009.07954.x","volume":"148","author":"SE Bates","year":"2010","unstructured":"Bates SE, Zhan Z, Steadman K, et al. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol. 2010;148(2):256\u201367.","journal-title":"Br J Haematol"},{"issue":"12","key":"962_CR51","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1158\/1078-0432.CCR-08-2785","volume":"15","author":"HM Prince","year":"2009","unstructured":"Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res. 2009;15(12):3958\u201369.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"962_CR52","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41571-019-0190-8","volume":"16","author":"D Sermer","year":"2019","unstructured":"Sermer D, Pasqualucci L, Wendel HG, Melnick A, Younes A. Emerging epigenetic-modulating therapies in lymphoma. Nat Rev Clin Oncol. 2019;16(8):494\u2013507.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"962_CR53","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10637-017-0552-y","volume":"36","author":"J Zhou","year":"2018","unstructured":"Zhou J, Zhang C, Sui X, et al. Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK\/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway. Invest New Drugs. 2018;36(4):571\u201380.","journal-title":"Invest New Drugs"},{"issue":"8","key":"962_CR54","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi Y, Dong M, Hong X, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26(8):1766\u201371.","journal-title":"Ann Oncol"},{"issue":"2","key":"962_CR55","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.hoc.2016.11.002","volume":"31","author":"E Marchi","year":"2017","unstructured":"Marchi E, Raufi AG, O\u2019Connor OA. Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma. Hematol Oncol Clin North Am. 2017;31(2):359\u201375.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"962_CR56","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","volume":"10","author":"Y Shi","year":"2017","unstructured":"Shi Y, Jia B, Xu W, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol. 2017;10(1):69.","journal-title":"J Hematol Oncol"},{"key":"962_CR57","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2147\/OTT.S93528","volume":"10","author":"TS Chan","year":"2017","unstructured":"Chan TS, Tse E, Kwong YL. Chidamide in the treatment of peripheral T-cell lymphoma. Onco Targets Ther. 2017;10:347\u201352.","journal-title":"Onco Targets Ther"},{"issue":"3","key":"962_CR58","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/17474086.2019.1583102","volume":"12","author":"H Ma","year":"2019","unstructured":"Ma H, O\u2019Connor OA, Marchi E. New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination. Expert Rev Hematol. 2019;12(3):137\u201346.","journal-title":"Expert Rev Hematol"},{"issue":"21","key":"962_CR59","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","volume":"25","author":"EA Olsen","year":"2007","unstructured":"Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109\u201315.","journal-title":"J Clin Oncol"},{"issue":"1","key":"962_CR60","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/bjh.12326","volume":"162","author":"Y Oki","year":"2013","unstructured":"Oki Y, Younes A, Copeland A, et al. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2013;162(1):138\u201341.","journal-title":"Br J Haematol"},{"issue":"3","key":"962_CR61","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00277-014-2009-0","volume":"93","author":"G Hopfinger","year":"2014","unstructured":"Hopfinger G, Nosslinger T, Lang A, et al. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed\/refractory peripheral T cell lymphoma (PTCL): report of a phase I\/II trial. Ann Hematol. 2014;93(3):459\u201362.","journal-title":"Ann Hematol"},{"issue":"4","key":"962_CR62","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1080\/10428194.2016.1222375","volume":"58","author":"KL Chan","year":"2017","unstructured":"Chan KL, van der Weyden C, Khoo C, et al. Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement. Leuk Lymphoma. 2017;58(4):996\u20138.","journal-title":"Leuk Lymphoma"},{"key":"962_CR63","first-page":"8175957","volume":"2016","author":"C Irle","year":"2016","unstructured":"Irle C, Weintraub J. Long-term treatment with romidepsin in patients with peripheral T-cell lymphoma. Case Rep Hematol. 2016;2016:8175957.","journal-title":"Case Rep Hematol"},{"issue":"1","key":"962_CR64","first-page":"22","volume":"6","author":"L Barbarotta","year":"2015","unstructured":"Barbarotta L, Hurley K. Romidepsin for the treatment of peripheral T-cell lymphoma. J Adv Pract Oncol. 2015;6(1):22\u201336.","journal-title":"J Adv Pract Oncol"},{"issue":"9","key":"962_CR65","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1634\/theoncologist.2015-0043","volume":"20","author":"SP Iyer","year":"2015","unstructured":"Iyer SP, Foss FF. Romidepsin for the treatment of peripheral T-cell lymphoma. Oncologist. 2015;20(9):1084\u201391.","journal-title":"Oncologist"},{"issue":"6","key":"962_CR66","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30(6):631\u20136.","journal-title":"J Clin Oncol"},{"key":"962_CR67","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1756-8722-7-11","volume":"7","author":"B Coiffier","year":"2014","unstructured":"Coiffier B, Pro B, Prince HM, et al. Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014;7:11.","journal-title":"J Hematol Oncol"},{"issue":"22","key":"962_CR68","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","volume":"117","author":"RL Piekarz","year":"2011","unstructured":"Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827\u201334.","journal-title":"Blood"},{"key":"962_CR69","doi-asserted-by":"crossref","unstructured":"Laribi K, Alani M, Truong C, Baugier de Materre A. Recent advances in the treatment of peripheral T-cell lymphoma. Oncologist. 2018. 23(9): 1039\u201353.","DOI":"10.1634\/theoncologist.2017-0524"},{"issue":"4","key":"962_CR70","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/S2352-3026(15)00023-X","volume":"2","author":"J Dupuis","year":"2015","unstructured":"Dupuis J, Morschhauser F, Ghesquieres H, et al. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b\/2 study. Lancet Haematol. 2015;2(4):e160\u20135.","journal-title":"Lancet Haematol"},{"issue":"9","key":"962_CR71","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-14-2249","volume":"21","author":"S Jain","year":"2015","unstructured":"Jain S, Jirau-Serrano X, Zullo KM, et al. Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma. Clin Cancer Res. 2015;21(9):2096\u2013106.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"962_CR72","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","volume":"131","author":"JE Amengual","year":"2018","unstructured":"Amengual JE, Lichtenstein R, Lue J, et al. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 2018;131(4):397\u2013407.","journal-title":"Blood"},{"issue":"4","key":"962_CR73","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/hon.2320","volume":"35","author":"B Pro","year":"2017","unstructured":"Pro B, Horwitz SM, Prince HM, et al. Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. Hematol Oncol. 2017;35(4):914\u20137.","journal-title":"Hematol Oncol"},{"issue":"6","key":"962_CR74","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.13222","volume":"168","author":"F Foss","year":"2015","unstructured":"Foss F, Advani R, Duvic M, et al. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015;168(6):811\u20139.","journal-title":"Br J Haematol"},{"issue":"23","key":"962_CR75","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O'Connor","year":"2015","unstructured":"O\u2019Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33(23):2492\u20139.","journal-title":"J Clin Oncol"},{"issue":"5","key":"962_CR76","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/CCO.0000000000000469","volume":"30","author":"C Gisselbrecht","year":"2018","unstructured":"Gisselbrecht C, Sibon D. New perspectives in the therapeutic approach of peripheral T-cell lymphoma. Curr Opin Oncol. 2018;30(5):285\u201391.","journal-title":"Curr Opin Oncol"},{"key":"962_CR77","doi-asserted-by":"publisher","first-page":"6731","DOI":"10.2147\/CMAR.S149241","volume":"10","author":"PB Allen","year":"2018","unstructured":"Allen PB, Lechowicz MJ. Hematologic toxicity is rare in relapsed patients treated with belinostat: a systematic review of belinostat toxicity and safety in peripheral T-cell lymphomas. Cancer Manag Res. 2018;10:6731\u201342.","journal-title":"Cancer Manag Res"},{"key":"962_CR78","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/CMAR.S85351","volume":"7","author":"P Reimer","year":"2015","unstructured":"Reimer P. New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat. Cancer Manag Res. 2015;7:145\u201351.","journal-title":"Cancer Manag Res"},{"issue":"7051","key":"962_CR79","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nature03841","volume":"436","author":"M Braig","year":"2005","unstructured":"Braig M, Lee S, Loddenkemper C, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature. 2005;436(7051):660\u20135.","journal-title":"Nature"},{"issue":"4","key":"962_CR80","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.molcel.2012.11.006","volume":"48","author":"JC Black","year":"2012","unstructured":"Black JC, Van Rechem C, Whetstine JR. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell. 2012;48(4):491\u2013507.","journal-title":"Mol Cell"},{"issue":"1","key":"962_CR81","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13072-018-0251-8","volume":"12","author":"BE Collins","year":"2019","unstructured":"Collins BE, Greer CB, Coleman BC, Sweatt JD. Histone H3 lysine K4 methylation and its role in learning and memory. Epigenetics Chromatin. 2019;12(1):7.","journal-title":"Epigenetics Chromatin"},{"key":"962_CR82","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/bs.acr.2016.05.001","volume":"131","author":"JN Nichol","year":"2016","unstructured":"Nichol JN, Dupere-Richer D, Ezponda T, Licht JD, Miller WH Jr. H3K27 methylation: a focal point of epigenetic deregulation in cancer. Adv Cancer Res. 2016;131:59\u201395.","journal-title":"Adv Cancer Res"},{"issue":"5","key":"962_CR83","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1084\/jem.20160894","volume":"214","author":"AB Moffitt","year":"2017","unstructured":"Moffitt AB, Ondrejka SL, McKinney M, et al. Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2. J Exp Med. 2017;214(5):1371\u201386.","journal-title":"J Exp Med"},{"key":"962_CR84","doi-asserted-by":"publisher","first-page":"12602","DOI":"10.1038\/ncomms12602","volume":"7","author":"A Roberti","year":"2016","unstructured":"Roberti A, Dobay MP, Bisig B, et al. Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations. Nat Commun. 2016;7:12602.","journal-title":"Nat Commun"},{"issue":"5","key":"962_CR85","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.cancergen.2015.01.005","volume":"208","author":"DJ Ford","year":"2015","unstructured":"Ford DJ, Dingwall AK. The cancer COMPASS: navigating the functions of MLL complexes in cancer. Cancer Genet. 2015;208(5):178\u201391.","journal-title":"Cancer Genet"},{"key":"962_CR86","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.gene.2017.06.056","volume":"627","author":"E Froimchuk","year":"2017","unstructured":"Froimchuk E, Jang Y, Ge K. Histone H3 lysine 4 methyltransferase KMT2D. Gene. 2017;627:337\u201342.","journal-title":"Gene"},{"issue":"7330","key":"962_CR87","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature09784","volume":"469","author":"R Margueron","year":"2011","unstructured":"Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in life. Nature. 2011;469(7330):343\u20139.","journal-title":"Nature"},{"issue":"5","key":"962_CR88","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/CCO.0000000000000390","volume":"29","author":"M Yamagishi","year":"2017","unstructured":"Yamagishi M, Uchimaru K. Targeting EZH2 in cancer therapy. Curr Opin Oncol. 2017;29(5):375\u201381.","journal-title":"Curr Opin Oncol"},{"issue":"22","key":"962_CR89","doi-asserted-by":"publisher","first-page":"4512","DOI":"10.1182\/blood-2012-08-450494","volume":"121","author":"J Yan","year":"2013","unstructured":"Yan J, Ng SB, Tay JL, et al. EZH2 overexpression in natural killer\/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. Blood. 2013;121(22):4512\u201320.","journal-title":"Blood"},{"issue":"2","key":"962_CR90","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.2651","volume":"18","author":"P Ntziachristos","year":"2012","unstructured":"Ntziachristos P, Tsirigos A, Van Vlierberghe P, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med. 2012;18(2):298\u2013301.","journal-title":"Nat Med"},{"issue":"7","key":"962_CR91","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1101\/gad.186411.111","volume":"26","author":"C Simon","year":"2012","unstructured":"Simon C, Chagraoui J, Krosl J, et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev. 2012;26(7):651\u20136.","journal-title":"Genes Dev"},{"issue":"7","key":"962_CR92","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3109\/10428194.2014.968780","volume":"56","author":"M Shi","year":"2015","unstructured":"Shi M, Shahsafaei A, Liu C, Yu H, Dorfman DM. Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases. Leuk Lymphoma. 2015;56(7):2087\u201391.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"962_CR93","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/PAI.0000000000000644","volume":"27","author":"S Fernandez-Pol","year":"2019","unstructured":"Fernandez-Pol S, Ma L, Joshi RP, Arber DA. A survey of somatic mutations in 41 genes in a cohort of T-cell lymphomas identifies frequent mutations in genes involved in epigenetic modification. Appl Immunohistochem Mol Morphol. 2019;27(6):416\u201322.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"9","key":"962_CR94","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ng.3358","volume":"47","author":"L Jiang","year":"2015","unstructured":"Jiang L, Gu ZH, Yan ZX, et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer\/T-cell lymphoma. Nat Genet. 2015;47(9):1061\u20136.","journal-title":"Nat Genet"},{"key":"962_CR95","doi-asserted-by":"crossref","unstructured":"van Riel B, Rosenbauer F. Epigenetic control of hematopoiesis: the PU.1 chromatin connection. Biol Chem. 2014. 395(11): 1265\u201374.","DOI":"10.1515\/hsz-2014-0195"},{"issue":"20","key":"962_CR96","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1182\/blood-2012-08-449140","volume":"121","author":"AR Chakraborty","year":"2013","unstructured":"Chakraborty AR, Robey RW, Luchenko VL, et al. MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor. Blood. 2013;121(20):4115\u201325.","journal-title":"Blood"},{"issue":"1","key":"962_CR97","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/npp.2012.112","volume":"38","author":"LD Moore","year":"2013","unstructured":"Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology. 2013;38(1):23\u201338.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"962_CR98","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.leukres.2005.08.012","volume":"30","author":"T Nagasawa","year":"2006","unstructured":"Nagasawa T, Zhang Q, Raghunath PN, et al. Multi-gene epigenetic silencing of tumor suppressor genes in T-cell lymphoma cells; delayed expression of the p16 protein upon reversal of the silencing. Leuk Res. 2006;30(3):303\u201312.","journal-title":"Leuk Res"},{"issue":"4","key":"962_CR99","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0002-9440(10)64629-9","volume":"157","author":"Q Zhang","year":"2000","unstructured":"Zhang Q, Raghunath PN, Vonderheid E, Odum N, Wasik MA. Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol. 2000;157(4):1137\u201346.","journal-title":"Am J Pathol"},{"issue":"26","key":"962_CR100","doi-asserted-by":"publisher","first-page":"19813","DOI":"10.1074\/jbc.M110.121988","volume":"285","author":"SA Hegazy","year":"2010","unstructured":"Hegazy SA, Wang P, Anand M, Ingham RJ, Gelebart P, Lai R. The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions. J Biol Chem. 2010;285(26):19813\u201320.","journal-title":"J Biol Chem"},{"issue":"19","key":"962_CR101","doi-asserted-by":"publisher","first-page":"6948","DOI":"10.1073\/pnas.0501959102","volume":"102","author":"Q Zhang","year":"2005","unstructured":"Zhang Q, Wang HY, Marzec M, Raghunath PN, Nagasawa T, Wasik MA. STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci USA. 2005;102(19):6948\u201353.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"962_CR102","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/nm1659","volume":"13","author":"Q Zhang","year":"2007","unstructured":"Zhang Q, Wang HY, Liu X, Wasik MA. STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. Nat Med. 2007;13(11):1341\u20138.","journal-title":"Nat Med"},{"issue":"29","key":"962_CR103","doi-asserted-by":"publisher","first-page":"11977","DOI":"10.1073\/pnas.1100319108","volume":"108","author":"Q Zhang","year":"2011","unstructured":"Zhang Q, Wang HY, Liu X, Bhutani G, Kantekure K, Wasik M. IL-2R common gamma-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK. Proc Natl Acad Sci USA. 2011;108(29):11977\u201382.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"962_CR104","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1182\/blood-2016-05-717793","volume":"129","author":"MT Werner","year":"2017","unstructured":"Werner MT, Zhao C, Zhang Q, Wasik MA. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target. Blood. 2017;129(7):823\u201331.","journal-title":"Blood"},{"issue":"3","key":"962_CR105","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1182\/blood-2005-08-007377","volume":"108","author":"Q Zhang","year":"2006","unstructured":"Zhang Q, Wang HY, Woetmann A, Raghunath PN, Odum N, Wasik MA. STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes. Blood. 2006;108(3):1058\u201364.","journal-title":"Blood"},{"issue":"22","key":"962_CR106","doi-asserted-by":"publisher","first-page":"8611","DOI":"10.1158\/0008-5472.CAN-09-2655","volume":"69","author":"C Ambrogio","year":"2009","unstructured":"Ambrogio C, Martinengo C, Voena C, et al. NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. Cancer Res. 2009;69(22):8611\u20139.","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"962_CR107","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.ctrv.2011.04.013","volume":"37","author":"T Schoofs","year":"2011","unstructured":"Schoofs T, Muller-Tidow C. DNA methylation as a pathogenic event and as a therapeutic target in AML. Cancer Treat Rev. 2011;37(Suppl 1):S13\u20138.","journal-title":"Cancer Treat Rev"},{"issue":"5929","key":"962_CR108","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1126\/science.1170116","volume":"324","author":"M Tahiliani","year":"2009","unstructured":"Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324(5929):930\u20135.","journal-title":"Science"},{"issue":"7347","key":"962_CR109","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nature10102","volume":"473","author":"WA Pastor","year":"2011","unstructured":"Pastor WA, Pape UJ, Huang Y, et al. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature. 2011;473(7347):394\u20137.","journal-title":"Nature"},{"issue":"6053","key":"962_CR110","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1126\/science.1212483","volume":"334","author":"A Inoue","year":"2011","unstructured":"Inoue A, Zhang Y. Replication-dependent loss of 5-hydroxymethylcytosine in mouse preimplantation embryos. Science. 2011;334(6053):194.","journal-title":"Science"},{"issue":"2","key":"962_CR111","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ng.2873","volume":"46","author":"T Palomero","year":"2014","unstructured":"Palomero T, Couronne L, Khiabanian H, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014;46(2):166\u201370.","journal-title":"Nat Genet"},{"issue":"5","key":"962_CR112","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s12185-015-1738-8","volume":"102","author":"M Sakata-Yanagimoto","year":"2015","unstructured":"Sakata-Yanagimoto M. Multistep tumorigenesis in peripheral T cell lymphoma. Int J Hematol. 2015;102(5):523\u20137.","journal-title":"Int J Hematol"},{"issue":"4","key":"962_CR113","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/ng.2916","volume":"46","author":"HY Yoo","year":"2014","unstructured":"Yoo HY, Sung MK, Lee SH, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(4):371\u20135.","journal-title":"Nat Genet"},{"issue":"9","key":"962_CR114","doi-asserted-by":"publisher","first-page":"e1006334","DOI":"10.1371\/journal.pgen.1006334","volume":"12","author":"SL Haney","year":"2016","unstructured":"Haney SL, Upchurch GM, Opavska J, et al. Dnmt3a is a haploinsufficient tumor suppressor in CD8+ peripheral T cell lymphoma. PLoS Genet. 2016;12(9):e1006334.","journal-title":"PLoS Genet"},{"key":"962_CR115","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-3-319-99716-2_2","volume":"176","author":"J Iqbal","year":"2019","unstructured":"Iqbal J, Amador C, McKeithan TW, Chan WC. Molecular and genomic landscape of peripheral T-cell lymphoma. Cancer Treat Res. 2019;176:31\u201368.","journal-title":"Cancer Treat Res"},{"key":"962_CR116","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1038\/bcj.2014.83","volume":"4","author":"H Muto","year":"2014","unstructured":"Muto H, Sakata-Yanagimoto M, Nagae G, et al. Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice. Blood Cancer J. 2014;4:e264.","journal-title":"Blood Cancer J"},{"issue":"1","key":"962_CR117","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","volume":"19","author":"W Xu","year":"2011","unstructured":"Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17\u201330.","journal-title":"Cancer Cell"},{"issue":"6","key":"962_CR118","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553\u201367.","journal-title":"Cancer Cell"},{"issue":"7","key":"962_CR119","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1158\/2159-8290.CD-13-0083","volume":"3","author":"RA Cairns","year":"2013","unstructured":"Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov. 2013;3(7):730\u201341.","journal-title":"Cancer Discov"},{"key":"962_CR120","doi-asserted-by":"crossref","unstructured":"Ueno H, Banchereau J, Vinuesa CG. Pathophysiology of T follicular helper cells in humans and mice. Nat Immunol, 2015, 16(2):142\u201352.","DOI":"10.1038\/ni.3054"},{"issue":"15","key":"962_CR121","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1182\/blood-2015-05-644591","volume":"126","author":"C Wang","year":"2015","unstructured":"Wang C, McKeithan TW, Gong Q, et al. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood. 2015;126(15):1741\u201352.","journal-title":"Blood"},{"key":"962_CR122","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3389\/fonc.2020.00898","volume":"10","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Lee D, Brimer T, Hussaini M, Sokol L. Genomics of peripheral T-cell lymphoma and its implications for personalized medicine. Front Oncol. 2020;10:898.","journal-title":"Front Oncol"},{"issue":"9","key":"962_CR123","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","volume":"123","author":"O Odejide","year":"2014","unstructured":"Odejide O, Weigert O, Lane AA, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014;123(9):1293\u20136.","journal-title":"Blood"},{"issue":"6","key":"962_CR124","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/bjh.13170","volume":"168","author":"M Cheminant","year":"2015","unstructured":"Cheminant M, Bruneau J, Kosmider O, et al. Efficacy of 5-azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma. Br J Haematol. 2015;168(6):913\u20136.","journal-title":"Br J Haematol"},{"issue":"21","key":"962_CR125","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","volume":"132","author":"F Lemonnier","year":"2018","unstructured":"Lemonnier F, Dupuis J, Sujobert P, et al. Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. Blood. 2018;132(21):2305\u20139.","journal-title":"Blood"},{"issue":"4","key":"962_CR126","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/hon.2319","volume":"35","author":"C Saillard","year":"2017","unstructured":"Saillard C, Guermouche H, Derrieux C, et al. Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma. Hematol Oncol. 2017;35(4):864\u20138.","journal-title":"Hematol Oncol"},{"key":"962_CR127","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13148-016-0237-y","volume":"8","author":"J Diesch","year":"2016","unstructured":"Diesch J, Zwick A, Garz AK, Palau A, Buschbeck M, Gotze KS. A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers. Clin Epigenetics. 2016;8:71.","journal-title":"Clin Epigenetics"},{"issue":"5","key":"962_CR128","first-page":"835","volume":"28","author":"K Uenogawa","year":"2011","unstructured":"Uenogawa K, Hatta Y, Arima N, et al. Azacitidine induces demethylation of p16INK4a and inhibits growth in adult T-cell leukemia\/lymphoma. Int J Mol Med. 2011;28(5):835\u20139.","journal-title":"Int J Mol Med"},{"issue":"11","key":"962_CR129","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1002\/cncr.23463","volume":"112","author":"E Jabbour","year":"2008","unstructured":"Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008;112(11):2341\u201351.","journal-title":"Cancer"},{"issue":"25","key":"962_CR130","doi-asserted-by":"publisher","first-page":"11797","DOI":"10.1073\/pnas.91.25.11797","volume":"91","author":"R Juttermann","year":"1994","unstructured":"Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2\u2019-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA. 1994;91(25):11797\u2013801.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"962_CR131","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.yexcr.2017.12.022","volume":"364","author":"J Yan","year":"2018","unstructured":"Yan J, Zhang J, Zhang X, et al. SPARC is down-regulated by DNA methylation and functions as a tumor suppressor in T-cell lymphoma. Exp Cell Res. 2018;364(2):125\u201332.","journal-title":"Exp Cell Res"},{"issue":"11","key":"962_CR132","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1016\/j.biochi.2012.05.029","volume":"94","author":"MR Hassler","year":"2012","unstructured":"Hassler MR, Klisaroska A, Kollmann K, et al. Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2\u2019-deoxycytidine in anaplastic large cell lymphoma. Biochimie. 2012;94(11):2297\u2013307.","journal-title":"Biochimie"},{"issue":"9","key":"962_CR133","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/sj.leu.2404323","volume":"20","author":"Y Han","year":"2006","unstructured":"Han Y, Amin HM, Frantz C, et al. Restoration of shp1 expression by 5-AZA-2\u2019-deoxycytidine is associated with downregulation of JAK3\/STAT3 signaling in ALK-positive anaplastic large cell lymphoma. Leukemia. 2006;20(9):1602\u20139.","journal-title":"Leukemia"},{"issue":"20","key":"962_CR134","doi-asserted-by":"publisher","first-page":"5506","DOI":"10.1182\/blood-2011-02-336891","volume":"118","author":"M Kalac","year":"2011","unstructured":"Kalac M, Scotto L, Marchi E, et al. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood. 2011;118(20):5506\u201316.","journal-title":"Blood"},{"issue":"8","key":"962_CR135","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-15-1435","volume":"22","author":"S Rozati","year":"2016","unstructured":"Rozati S, Cheng PF, Widmer DS, Fujii K, Levesque MP, Dummer R. Romidepsin and azacitidine synergize in their epigenetic modulatory effects to induce apoptosis in CTCL. Clin Cancer Res. 2016;22(8):2020\u201331.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"962_CR136","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/bjh.13566","volume":"171","author":"E Marchi","year":"2015","unstructured":"Marchi E, Zullo KM, Amengual JE, et al. The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma. Br J Haematol. 2015;171(2):215\u201326.","journal-title":"Br J Haematol"},{"issue":"3","key":"962_CR137","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/14712598.2019.1572746","volume":"19","author":"Y Ito","year":"2019","unstructured":"Ito Y, Makita S, Tobinai K. Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019;19(3):197\u2013209.","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"962_CR138","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.18632\/oncotarget.23386","volume":"9","author":"BC Valdez","year":"2018","unstructured":"Valdez BC, Li Y, Murray D, et al. Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells. Oncotarget. 2018;9(3):3908\u201321.","journal-title":"Oncotarget"},{"issue":"17","key":"962_CR139","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood.2019001285","volume":"134","author":"OA O'Connor","year":"2019","unstructured":"O\u2019Connor OA, Falchi L, Lue JK, et al. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood. 2019;134(17):1395\u2013405.","journal-title":"Blood"},{"issue":"19","key":"962_CR140","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.4161\/cc.5.19.3340","volume":"5","author":"Y Saito","year":"2006","unstructured":"Saito Y, Jones PA. Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle. 2006;5(19):2220\u20132.","journal-title":"Cell Cycle"},{"key":"962_CR141","doi-asserted-by":"crossref","unstructured":"Fuchs S, Naderi J, Meggetto F. Non-coding RNA networks in ALK-positive anaplastic-large cell lymphoma. Int J Mol Sci. 2019. 20(9).","DOI":"10.3390\/ijms20092150"},{"issue":"15","key":"962_CR142","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.1158\/0008-5472.CAN-12-0803","volume":"72","author":"C Baer","year":"2012","unstructured":"Baer C, Claus R, Frenzel LP, et al. Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia. Cancer Res. 2012;72(15):3775\u201385.","journal-title":"Cancer Res"},{"issue":"5","key":"962_CR143","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood-2002-05-1343","volume":"101","author":"R Chiarle","year":"2003","unstructured":"Chiarle R, Gong JZ, Guasparri I, et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood. 2003;101(5):1919\u201327.","journal-title":"Blood"},{"issue":"4","key":"962_CR144","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/path.4539","volume":"236","author":"O Merkel","year":"2015","unstructured":"Merkel O, Hamacher F, Griessl R, et al. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. J Pathol. 2015;236(4):445\u201356.","journal-title":"J Pathol"},{"key":"962_CR145","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3389\/fgene.2012.00233","volume":"3","author":"RL Yim","year":"2012","unstructured":"Yim RL, Kwong YL, Wong KY, Chim CS. DNA methylation of tumor suppressive miRNAs in non-Hodgkin\u2019s lymphomas. Front Genet. 2012;3:233.","journal-title":"Front Genet"},{"issue":"24","key":"962_CR146","doi-asserted-by":"publisher","first-page":"6627","DOI":"10.1182\/blood-2010-09-301994","volume":"117","author":"C Desjobert","year":"2011","unstructured":"Desjobert C, Renalier MH, Bergalet J, et al. MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression. Blood. 2011;117(24):6627\u201337.","journal-title":"Blood"},{"key":"962_CR147","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1756-8722-6-16","volume":"6","author":"KY Wong","year":"2013","unstructured":"Wong KY, Yim RL, Kwong YL, et al. Epigenetic inactivation of the MIR129-2 in hematological malignancies. J Hematol Oncol. 2013;6:16.","journal-title":"J Hematol Oncol"},{"key":"962_CR148","doi-asserted-by":"crossref","unstructured":"Bueno MJ, P\u00e9rez de Castro I, G\u00f3mez de Cedr\u00f3n M, et al. Genetic and epigenetic silencing of MicroRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell. 2016. 29(4): 607\u20138.","DOI":"10.1016\/j.ccell.2016.03.013"},{"issue":"12","key":"962_CR149","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1111\/j.1582-4934.2011.01274.x","volume":"15","author":"CS Chim","year":"2011","unstructured":"Chim CS, Wong KY, Leung CY, et al. Epigenetic inactivation of the hsa-miR-203 in haematological malignancies. J Cell Mol Med. 2011;15(12):2760\u20137.","journal-title":"J Cell Mol Med"},{"issue":"5","key":"962_CR150","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3324\/haematol.2010.028605","volume":"96","author":"D Sasaki","year":"2011","unstructured":"Sasaki D, Imaizumi Y, Hasegawa H, et al. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia\/lymphoma as a target for epigenetic therapy. Haematologica. 2011;96(5):712\u20139.","journal-title":"Haematologica"},{"issue":"2","key":"962_CR151","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3324\/haematol.2018.195131","volume":"104","author":"C Hoareau-Aveilla","year":"2019","unstructured":"Hoareau-Aveilla C, Quelen C, Congras A, et al. miR-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells. Haematologica. 2019;104(2):347\u201359.","journal-title":"Haematologica"},{"key":"962_CR152","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.taap.2018.05.002","volume":"350","author":"SM Attia","year":"2018","unstructured":"Attia SM, Al-Hamamah MA, Alotaibi MR, et al. Investigation of belinostat-induced genomic instability by molecular cytogenetic analysis and pathway-focused gene expression profiling. Toxicol Appl Pharmacol. 2018;350:43\u201351.","journal-title":"Toxicol Appl Pharmacol"},{"key":"962_CR153","doi-asserted-by":"crossref","unstructured":"Hoareau-Aveilla C, Meggetto F. Crosstalk between microRNA and DNA methylation offers potential biomarkers and targeted therapies in ALK-positive lymphomas. Cancers (Basel). 2017. 9(8).","DOI":"10.3390\/cancers9080100"},{"issue":"18","key":"962_CR154","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1182\/blood.2019791475","volume":"134","author":"CJ Lio","year":"2019","unstructured":"Lio CJ, Yuita H, Rao A. Dysregulation of the TET family of epigenetic regulators in lymphoid and myeloid malignancies. Blood. 2019;134(18):1487\u201397.","journal-title":"Blood"},{"key":"962_CR155","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ceb.2015.10.009","volume":"37","author":"M Ko","year":"2015","unstructured":"Ko M, An J, Rao A. DNA methylation and hydroxymethylation in hematologic differentiation and transformation. Curr Opin Cell Biol. 2015;37:91\u2013101.","journal-title":"Curr Opin Cell Biol"},{"issue":"12","key":"962_CR156","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","volume":"33","author":"Y Watatani","year":"2019","unstructured":"Watatani Y, Sato Y, Miyoshi H, et al. Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia. 2019;33(12):2867\u201383.","journal-title":"Leukemia"},{"issue":"20","key":"962_CR157","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.1158\/1078-0432.CCR-18-0536","volume":"24","author":"ML Amaya","year":"2018","unstructured":"Amaya ML, Pollyea DA. Targeting the IDH2 pathway in acute myeloid leukemia. Clin Cancer Res. 2018;24(20):4931\u20136.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"962_CR158","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/leu.2016.275","volume":"31","author":"BC Medeiros","year":"2017","unstructured":"Medeiros BC, Fathi AT, DiNardo CD, Pollyea DA, Chan SM, Swords R. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. 2017;31(2):272\u201381.","journal-title":"Leukemia"},{"issue":"10","key":"962_CR159","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/nm.3940","volume":"21","author":"J Zhang","year":"2015","unstructured":"Zhang J, Dominguez-Sola D, Hussein S, et al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat Med. 2015;21(10):1190\u20138.","journal-title":"Nat Med"},{"issue":"7360","key":"962_CR160","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10351","volume":"476","author":"RD Morin","year":"2011","unstructured":"Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360):298\u2013303.","journal-title":"Nature"},{"key":"962_CR161","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.canlet.2019.05.024","volume":"458","author":"RJ Fagan","year":"2019","unstructured":"Fagan RJ, Dingwall AK. COMPASS ascending: emerging clues regarding the roles of MLL3\/KMT2C and MLL2\/KMT2D proteins in cancer. Cancer Lett. 2019;458:56\u201365.","journal-title":"Cancer Lett"},{"issue":"6016","key":"962_CR162","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1126\/science.1198056","volume":"331","author":"DW Parsons","year":"2011","unstructured":"Parsons DW, Li M, Zhang X, et al. The genetic landscape of the childhood cancer medulloblastoma. Science. 2011;331(6016):435\u20139.","journal-title":"Science"},{"issue":"7409","key":"962_CR163","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature11329","volume":"488","author":"TJ Pugh","year":"2012","unstructured":"Pugh TJ, Weeraratne SD, Archer TC, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 2012;488(7409):106\u201310.","journal-title":"Nature"},{"key":"962_CR164","doi-asserted-by":"crossref","unstructured":"Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013. 499(7456): 43\u20139.","DOI":"10.1038\/nature12222"},{"issue":"1","key":"962_CR165","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","volume":"277","author":"O Witt","year":"2009","unstructured":"Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets. Cancer Lett. 2009;277(1):8\u201321.","journal-title":"Cancer Lett"},{"issue":"12","key":"962_CR166","doi-asserted-by":"publisher","first-page":"7436","DOI":"10.1074\/jbc.M808999200","volume":"284","author":"VD Kekatpure","year":"2009","unstructured":"Kekatpure VD, Dannenberg AJ, Subbaramaiah K. HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J Biol Chem. 2009;284(12):7436\u201345.","journal-title":"J Biol Chem"},{"issue":"3","key":"962_CR167","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.3390\/molecules20033898","volume":"20","author":"M Mottamal","year":"2015","unstructured":"Mottamal M, Zheng S, Huang TL, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015;20(3):3898\u2013941.","journal-title":"Molecules"},{"issue":"3","key":"962_CR168","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1474-4422(11)70013-8","volume":"10","author":"DJ Bonda","year":"2011","unstructured":"Bonda DJ, Lee HG, Camins A, et al. The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations. Lancet Neurol. 2011;10(3):275\u20139.","journal-title":"Lancet Neurol"},{"issue":"4","key":"962_CR169","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrm3293","volume":"13","author":"RH Houtkooper","year":"2012","unstructured":"Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol. 2012;13(4):225\u201338.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"962_CR170","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4155\/fmc.14.44","volume":"6","author":"J Hu","year":"2014","unstructured":"Hu J, Jing H, Lin H. Sirtuin inhibitors as anticancer agents. Future Med Chem. 2014;6(8):945\u201366.","journal-title":"Future Med Chem"},{"key":"962_CR171","unstructured":"The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance."},{"issue":"2","key":"962_CR172","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jss.2010.12.035","volume":"174","author":"ZR Lian","year":"2012","unstructured":"Lian ZR, Xu YF, Wang XB, Gong JP, Liu ZJ. Suppression of histone deacetylase 11 promotes expression of IL-10 in Kupffer cells and induces tolerance following orthotopic liver transplantation in rats. J Surg Res. 2012;174(2):359\u201368.","journal-title":"J Surg Res"},{"issue":"4","key":"962_CR173","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/leu.2013.291","volume":"28","author":"ZX Yan","year":"2014","unstructured":"Yan ZX, Wu LL, Xue K, et al. MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma. Leukemia. 2014;28(4):880\u20137.","journal-title":"Leukemia"},{"issue":"37","key":"962_CR174","doi-asserted-by":"publisher","first-page":"16228","DOI":"10.1073\/pnas.1009719107","volume":"107","author":"O Merkel","year":"2010","unstructured":"Merkel O, Hamacher F, Laimer D, et al. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proc Natl Acad Sci USA. 2010;107(37):16228\u201333.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"962_CR175","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3324\/haematol.2013.088286","volume":"99","author":"E Spaccarotella","year":"2014","unstructured":"Spaccarotella E, Pellegrino E, Ferracin M, et al. STAT3-mediated activation of microRNA cluster 17\u201392 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma. Haematologica. 2014;99(1):116\u201324.","journal-title":"Haematologica"},{"issue":"26","key":"962_CR176","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.1182\/blood-2011-05-354654","volume":"118","author":"H Matsuyama","year":"2011","unstructured":"Matsuyama H, Suzuki HI, Nishimori H, et al. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. Blood. 2011;118(26):6881\u201392.","journal-title":"Blood"},{"issue":"12","key":"962_CR177","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1038\/leu.2011.168","volume":"25","author":"E Dejean","year":"2011","unstructured":"Dejean E, Renalier MH, Foisseau M, et al. Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas. Leukemia. 2011;25(12):1882\u201390.","journal-title":"Leukemia"},{"issue":"5","key":"962_CR178","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.ajpath.2012.01.008","volume":"180","author":"D Vishwamitra","year":"2012","unstructured":"Vishwamitra D, Li Y, Wilson D, et al. MicroRNA 96 is a post-transcriptional suppressor of anaplastic lymphoma kinase expression. Am J Pathol. 2012;180(5):1772\u201380.","journal-title":"Am J Pathol"},{"issue":"12","key":"962_CR179","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1182\/blood-2012-08-447375","volume":"122","author":"C Liu","year":"2013","unstructured":"Liu C, Iqbal J, Teruya-Feldstein J, et al. MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. Blood. 2013;122(12):2083\u201392.","journal-title":"Blood"},{"issue":"10","key":"962_CR180","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1038\/leu.2013.121","volume":"27","author":"HI Suzuki","year":"2013","unstructured":"Suzuki HI, Matsuyama H, Noguchi M, et al. Computational dissection of distinct microRNA activity signatures associated with peripheral T cell lymphoma subtypes. Leukemia. 2013;27(10):2107\u201311.","journal-title":"Leukemia"},{"issue":"4","key":"962_CR181","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/bjh.14824","volume":"182","author":"R Manso","year":"2018","unstructured":"Manso R, Mart\u00ednez-Magunacelaya N, Chamizo C, Rojo F, Piris M\u00c1, Rodriguez-Pinilla SM. Mutual regulation between BCL6 and a specific set of miRNAs controls T(FH) phenotype in peripheral T-cell lymphoma. Br J Haematol. 2018;182(4):587\u201390.","journal-title":"Br J Haematol"},{"issue":"11","key":"962_CR182","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/bcj.2014.78","volume":"4","author":"MA Laginestra","year":"2014","unstructured":"Laginestra MA, Piccaluga PP, Fuligni F, et al. Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified. Blood Cancer J. 2014;4(11):259.","journal-title":"Blood Cancer J"},{"issue":"4","key":"962_CR183","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3233\/CBM-160126","volume":"18","author":"Y Lin","year":"2017","unstructured":"Lin Y, Chen WM, Wang C, Chen XY. MicroRNA profiling in peripheral T-cell lymphoma, not otherwise specified. Cancer Biomark. 2017;18(4):339\u201347.","journal-title":"Cancer Biomark"},{"issue":"4","key":"962_CR184","first-page":"2055","volume":"35","author":"K Reddemann","year":"2015","unstructured":"Reddemann K, Gola D, Schillert A, et al. Dysregulation of microRNAs in angioimmunoblastic T-cell lymphoma. Anticancer Res. 2015;35(4):2055\u201361.","journal-title":"Anticancer Res"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-020-00962-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13148-020-00962-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-020-00962-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T12:04:34Z","timestamp":1605009874000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-020-00962-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,7]]},"references-count":184,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["962"],"URL":"https:\/\/doi.org\/10.1186\/s13148-020-00962-x","relation":{},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"value":"1868-7075","type":"print"},{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,7]]},"assertion":[{"value":"14 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}